Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Huan Jing Ke Xue ; 43(9):4597-4607, 2022.
Article in Chinese | PubMed | ID: covidwho-2025656

ABSTRACT

The degradation of chloroquine phosphate (CQP), an anti-COVID-19 drug, was investigated in a UV-activated persulfate system (UV/PS). The second-order rate constants of CQP with hydroxyl radicals (HO·) and sulfate radicals (SO(4)(-)·) were determined using a competition kinetics experiment, and the effects of persulfate concentration, pH, and inorganic anions on the degradation of CQP were also systematically studied. Furthermore, a kinetic model was established to predict the concentration of CQP and major free radicals to explore its mechanism of influence. The results showed that the degradation efficiency of CQP could reach 91.3% after 10 min under UV/PS, which was significantly higher than that under UV, sunlight, or PS alone. At pH=6.9, the second-order rate reaction constants of CQP with HO· and SO(4)(-)· were 8.9×10(9) L·(mol·s)(-1)and 1.4×10(10) L·(mol·s)(-1), respectively, and the main active species was SO(4)(-)·. The degradation rate of CQP increased with increasing concentrations of PS and decreased with the addition of HCO(3)(-) and Cl(-). The removal efficiency of CQP was inhibited under stronger alkaline conditions. N-de-ethylation, cleavage of the C-N bond, and hydrogen ion were proposed as the principal pathways of CQP degradation based on LC-MS analysis. The mineralization rate of CQP could be improved by increasing PS concentration and pH values. This study could be helpful for the treatment of anti-COVID-19 pharmaceutical wastewater.

2.
Zhonghua Kou Qiang Yi Xue Za Zhi ; 57(5): 455-461, 2022 May 09.
Article in Chinese | MEDLINE | ID: covidwho-1818247

ABSTRACT

Today, there is greater awareness on the association between oral diseases and respiration diseases after the outbreak of COVID-19. However, confusion regarding the oral health management and medical risk prevention for patients with chronic airway diseases has been remained among dental clinicians. Therefore, the dental experts of the Fifth General Dentistry Special Committee, Chinese Stomatological Association, combined with the experts of respiratory and critical care medicine, undertook the formation of consensus on the oral health management of patients with chronic airway diseases in order to help dental clinicians to evaluate medical risks and make better treatment decision in clinical practice. In the present consensus report, the relationship of oral diseases and chronic airway diseases, the oral health management and the treatment recommendations of patients with chronic airway diseases are provided.


Subject(s)
COVID-19 , Oral Medicine , Consensus , Humans , Oral Health
3.
Zhonghua Zhong Liu Za Zhi ; 42(4): 288-291, 2020 Apr 23.
Article in Chinese | MEDLINE | ID: covidwho-1379995

ABSTRACT

The outbreak of 2019 novel coronavirus disease (COVID-19) is spreading rapidly. In order to prevent cluster outbreaks, the government strengthened the management and control of personnel mobility, which had a great impact on the examination and treatment of breast cancer patients. This paper discusses how to realize scientific health management of breast cancer patients outside the hospital based on the existing epidemic situation, characteristics of breast cancer patients and public health safety factors. The breast cancer patients should synthetically consider the epidemic prevention situation of inhabitance, the disease stage and previous therapeutic schedule to decide the next therapeutic schedule. If necessary, after professional discussion and communication between doctors and patients online or offline, the hospital visiting time should be delayed through seeking alternative treatment schemes, and psychological counseling for patients should be paid attention to at the same time.


Subject(s)
Breast Neoplasms , Coronavirus Infections , Coronavirus , Disease Outbreaks/prevention & control , Pandemics/prevention & control , Pneumonia, Viral , Telemedicine , Ambulatory Care , Betacoronavirus , Breast Neoplasms/diagnosis , Breast Neoplasms/psychology , Breast Neoplasms/therapy , COVID-19 , China , Coronavirus Infections/epidemiology , Humans , Pneumonia, Viral/epidemiology , SARS-CoV-2
4.
Zhonghua Zhong Liu Za Zhi ; 43(2): 218-223, 2021 Feb 23.
Article in Chinese | MEDLINE | ID: covidwho-1084794

ABSTRACT

Objective: To explore the latest progress of oncology drug clinical trials in China under COVID-19, as well as to provide decision-making evidence for related stakeholders. Research progress of oncology drug trials and approved cancer drugs in China in 2020 were systematically summarized and compared with 2019. Methods: Information Disclosure Platform for Drug Clinical Studies and China Food and Drug Administration Query System for Domestic and Imported Drug were searched for registered clinical trials and approved oncology drugs, respectively. The trial scope, stage, drug type, effect and mechanism of domestic and global pharmaceutical enterprises were compared between 2019 and 2020. Results: A total of 722 cancer drug trials registered in China in 2020, with an annual growth rate of 52.3%, accounting for 28.3% of all registered trials. Among them, 603 (83.5%) trials were initiated by domestic pharmaceutical enterprises, and 105 (14.5%) were international multicenter trials, phase I trials accounted for 44.5%. For all those trials, there were 458 cancer drug varieties, with an annual growth rate of 36.7%, and 361 (85.8%) were developed by domestic enterprises. Most of the investigational products were therapeutic innovative drugs (77.1%), major in tumor treatment (92.8%). In terms of mechanism, targeted drugs were the most popular, accounting for 76.6%, and programmed cell death-1 (PD-1) and epithelial growth factor receptor (EGFR) were the most common targets. In addition, there were 19 anticancer drugs from 17 companies approved in China in 2019, with 10 drugs from domestic companies. Lung cancer and breast cancer are the most common indications for both registered trials and marketed drugs. No statistically significant differences were found between 2020 and 2019 in terms of the distribution of trial sponsor, scope and stage, as well as the distribution of drug type, effect and mechanism (P>0.05). Conclusions: During the Covid-19 epidemic period, clinical trials of oncology drugs in China progress smoothly and maintain a high growth rate. Series of innovative products obtained by domestic enterprises in 2020 is the main driving force of development of oncology drug clinical trials in China.


Subject(s)
Antineoplastic Agents , COVID-19 , Neoplasms , Antineoplastic Agents/therapeutic use , China , Clinical Trials as Topic , Humans , Medical Oncology , Neoplasms/drug therapy , SARS-CoV-2 , United States
5.
Eur Rev Med Pharmacol Sci ; 24(8): 4576-4584, 2020 04.
Article in English | MEDLINE | ID: covidwho-203343

ABSTRACT

Coronavirus Disease-2019 (COVID-19) caused by SARS-CoV-2 infection has rapidly spread all over the world, in just two months. As of 27 March, globally, 509,164 cases confirmed included 23,335 deaths in approximately 150 countries. Recently, WHO has defined COVID-19 as a global pandemic, and considerable researches have focused on the identification and prevention of SARS-CoV-2. As a result, accumulated publications successively reported their early findings, leading to the constant updating of information, which might make confusion for readers. Therefore, this review summarized the current researches about the genomic evolution, variation of SARS-CoV-2, and demonstrated its viral structure for pathogenesis. Meanwhile, we analyzed the epidemiologic and clinical characteristics of COVID-19, in order to provide recommendations for present clinical treatments and inspirations for potential therapy options.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/epidemiology , Pneumonia, Viral/epidemiology , Angiotensin-Converting Enzyme 2 , Betacoronavirus/classification , COVID-19 , Coronavirus Infections/pathology , Coronavirus Infections/therapy , Coronavirus Infections/virology , Evolution, Molecular , Genome, Viral , Humans , Pandemics , Peptidyl-Dipeptidase A/chemistry , Phylogeny , Pneumonia, Viral/pathology , Pneumonia, Viral/therapy , Pneumonia, Viral/virology , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL